Granules drug gets USFDA nod

G Naga Sridhar Updated - August 30, 2022 at 02:13 PM.

Approved drug from Granules is bioequivalent of Imodium multi-symptom relief tablets

File image | Photo Credit: vladwel

Granules India has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for loperamide hydrochloride and simethicone tablets.

The approved product is the bioequivalent of the reference listed drug Imodium multi-symptom relief tablets of Johnson & Johnson Consumer Inc, McNeil Consumer Healthcare Division.

The Imodium multi-symptom relief brand and store brands had combined US sales of approximately $60 million for the most recent 12 months. 

Loperamide hydrochloride and simethicone tablets are indicated to relieve symptoms of diarrhoea plus bloating, pressure and cramps, commonly referred to as gas.

Hyderabad-based Granules now has 52 ANDA approvals from the USFDA, according to a release.

Published on August 30, 2022 08:43

This is a Premium article available exclusively to our subscribers.

Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

You have reached your free article limit.

Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

You have reached your free article limit.
Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

TheHindu Businessline operates by its editorial values to provide you quality journalism.

This is your last free article.